Table 4.
Standardized | Unstandardized | SE | p-value | |
---|---|---|---|---|
Model: Benefits Y1 benefits R2=0.22, p<.001; Y2 CRCS R2=0.11, p<.001 | ||||
BL PS -> Y2 CRCS (path4) | 0.188 | 0.256 | 0.113 | 0.024 |
BL PS -> Y1 benefits (path1) | 0.001 | 0.001 | 0.034 | 0.983 |
BL benefits -> Y1 benefits | 0.527 | 0.503 | 0.038 | <0.001 |
Y1 benefits -> Y2 CRCS (path2) | 0.304 | 0.446 | 0.077 | <0.001 |
BL CRCS -> Y1 benefits | 0.323 | 0.220 | 0.037 | <0.001 |
BL CRCS -> Y2 CRCS | 1.351 | 1.351 | 0.206 | <0.001 |
Study group -> Y1 benefits | −0.050 | −0.034 | 0.042 | 0.416 |
Study group -> Y2 CRCS | −0.178 | −0.178 | 0.160 | 0.265 |
BL Age -> Y1 benefits | −0.004 | −0.003 | 0.002 | 0.239 |
BL Age -> Y2 CRCS | 0.015 | 0.015 | 0.007 | 0.045 |
BL FamHx -> Y1 benefits | 0.036 | 0.024 | 0.046 | 0.597 |
BL FamHx -> Y2 CRCS | −0.002 | −0.002 | 0.155 | 0.992 |
Model: Barriers Y1 barriers R2=0.16, p<.001; Y2 CRCS R2=0.10, p<.001 | ||||
BL PS -> Y2 CRCS (path4) | 0.222 | 0.302 | 0.109 | 0.006 |
BL PS -> Y1 barriers (path1) | 0.022 | 0.029 | 0.047 | 0.538 |
BL barriers -> Y1 barriers | 0.488 | 0.486 | 0.035 | <0.001 |
Y1 barriers -> Y2 CRCS (path2) | −0.155 | −0.158 | 0.068 | 0.019 |
BL PS*barriers -> Y1 barriers (path3) | 0.079 | 0.108 | 0.041 | 0.009 |
BL CRCS -> Y1 barriers | −0.138 | −0.136 | 0.069 | 0.049 |
BL CRCS -> Y2 CRCS | 1.491 | 1.491 | 0.210 | <0.001 |
Study group -> Y1 barriers | 0.121 | 0.118 | 0.074 | 0.111 |
Study group -> Y2 CRCS | −0.170 | −0.170 | 0.154 | 0.269 |
BL Age -> Y1 barriers | −0.006 | −0.006 | 0.003 | 0.065 |
BL Age -> Y2 CRCS | 0.011 | 0.011 | 0.007 | 0.121 |
BL FamHx -> Y1 barriers | −0.052 | −0.051 | 0.081 | 0.524 |
BL FamHx -> Y2 CRCS | 0.012 | 0.012 | 0.159 | 0.942 |
Model: Self-efficacy (SE) Y1 SE R2=0.10, p<.001; Y2 CRCS R2=0.13, p<.001 | ||||
BL PS -> Y2 CRCS (path4) | 0.207 | 0.281 | 0.111 | 0.011 |
BL PS -> Y1 SE (path1) | 0.009 | 0.012 | 0.054 | 0.831 |
BL SE -> Y1 SE | 0.362 | 0.368 | 0.031 | <0.001 |
Y1 SE -> Y2 CRCS (path2) | 0.392 | 0.400 | 0.078 | <0.001 |
BL CRCS -> Y1 SE | 0.356 | 0.348 | 0.062 | <0.001 |
BL CRCS -> Y2 CRCS | 1.355 | 1.355 | 0.209 | <0.001 |
Study group -> Y1 SE | −0.013 | −0.013 | 0.075 | 0.867 |
Study group -> Y2 CRCS | −0.175 | −0.175 | 0.157 | 0.266 |
BL Age -> Y1 SE | 0.001 | 0.001 | 0.002 | 0.801 |
BL Age -> Y2 CRCS | 0.012 | 0.012 | 0.008 | 0.113 |
BL FamHx -> Y1 SE | −0.016 | −0.016 | 0.072 | 0.867 |
BL FamHx -> Y2 CRCS | 0.021 | 0.021 | 0.165 | 0.900 |
Model: Family Influence (Fam) Y1 Fam R2=0.15, p<.001; Y2 CRCS R2=0.11, p<.001 | ||||
BL PS -> Y2 CRCS (path4) | 0.165 | 0.225 | 0.117 | 0.055 |
BL PS -> Y1 Fam (path1) | 0.126 | 0.772 | 0.202 | 0.001 |
BL Fam -> Y1 Fam | 0.376 | 0.379 | 0.038 | <0.001 |
Y1 Fam -> Y2 CRCS (path2) | 0.268 | 0.059 | 0.018 | 0.001 |
BL CRCS -> Y1 Fam | 0.453 | 2.041 | 0.227 | <0.001 |
BL CRCS -> Y2 CRCS | 1.376 | 1.376 | 0.203 | <0.001 |
Study group -> Y1 Fam | −0.122 | −0.550 | 0.248 | 0.027 |
Study group -> Y2 CRCS | −0.148 | −0.148 | 0.160 | 0.356 |
BL Age -> Y1 Fam | −0.002 | −0.007 | 0.012 | 0.553 |
BL Age -> Y2 CRCS | 0.013 | 0.013 | 0.008 | 0.087 |
BL FamHx -> Y1 Fam | −0.063 | −0.285 | 0.329 | 0.386 |
BL FamHx -> Y2 CRCS | 0.037 | 0.037 | 0.159 | 0.815 |
Significant paths of interest are bolded.
PS=perceived susceptibility, BL=baseline, Y1=year 1 follow-up, Y2=year 2 follow-up, SE=self-efficacy, Fam=family influence, FamHx=family history of colorectal cancer, CRCS=colorectal cancer screening